6/24/2019 · Basel, June 24, 2019-In collaboration with Novartis, ENCORE-LF is a phase 2b trial that Conatus Pharmaceuticals Inc. conducted to evaluate emricasan (VAY785) in patients with decompensated NASH cirrhosis. Conatus announced this trial did not meet its primary endpoint of event-free survival relative to placebo.
6/25/2019 · The randomized, double-blind ENCORE-LF Phase 2b clinical trial, initiated in the second quarter of 2017, enrolled 217 patients with decompensated NASH cirrhosis. Patients were randomized 1:1:1 to …
ENCORE LF is a clear tan coloured liquid formulated as a high performance heavy duty low foaming detergent. A synergistic blend of powerful alkali and surfactants that quickly break up and solubilise heavy oily soils and greases. ENCORE LF is an excellent performer in mechanical auto floor scrubber applications, Conatus Pharmaceuticals Inc. (CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is …
6/24/2019 · Conatus Pharmaceuticals Inc. (CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial. Also, results from the 24-week extension in the company’s ENCORE-PH clinical trial of.
The randomized, double-blind ENCORE-LF Phase 2b clinical trial, initiated in the second quarter of 2017, enrolled 217 patients with decompensated NASH cirrhosis. Patients were randomized 1:1:1 to receive 5 mg of emricasan, 25 mg of emricasan, or placebo twice daily for at least 48 weeks. The trial was conducted at 73 U.S. sites.
The ENCORE-LF clinical trial is designed to evaluate safety, dosing and efficacy of emricasan in patients with decompensated NASH cirrhosis as an integral part of the company’s initial …
SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial. Also, results from the 24-week.
* conatus pharmaceuticals inc – top-line results from company’s encore-lf clinical trial of emricasan did not meet its primary endpoint * conatus pharmaceuticals inc – discontinuing further …
The ENCORE-LF clinical trial is designed to evaluate safety, dosing and efficacy of emricasan in patients with decompensated NASH cirrhosis as an integral part of the company’s initial registration strategy. The double-blind, placebo-controlled, trial is being conducted at approximately 90 U.S. clinical sites in approximately 210 patients …
